5 Key Takeaways
-
1
The AOA's report addresses ocular risks associated with glucagon-like peptide-1 receptor agonists (GLP-1s).
-
2
GLP-1s are linked to worsening diabetic retinopathy, nonarteritic anterior ischemic optic neuropathy, and neovascular age-related macular degeneration.
-
3
The report provides clinical recommendations for optometrists managing patients on GLP-1s, which are used for diabetes and weight loss.
-
4
As of 2024, 6% of adults in the U.S. are using GLP-1s, highlighting the importance of understanding their ocular risks.
-
5
The 9-page report includes discussions on systemic and ocular risks, as well as guidance for optometric practice.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.